Skin Abnormalities: Clinical Trials

18 trials for Skin Abnormalities, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed. 18 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 318Completed 18
Phase 24Completed 4

Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
TMB-001, Matching Vehicle - Ichthyosis
Phase 3CompletedLEO Pharma1532022-06-212026-05-22
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
QTORIN 3.9% rapamycin anhydrous gel, Vehicle - Pachyonychia Congenita
Phase 3CompletedPalvella Therapeutics, Inc.872021-11-292024-08-29
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Open Label Topical Beremagene Geperpavec (B-VEC) - Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
Phase 3CompletedKrystal Biotech, Inc.472021-05-252024-04-09
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
PTX-022 - Pachyonychia Congenita
Phase 3CompletedPalvella Therapeutics, Inc.362020-09-012024-08-29
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
Topical Beremagene Geperpavec, Placebo - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Phase 3CompletedKrystal Biotech, Inc.312020-08-172023-02-17
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
EB-101 - Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Phase 3CompletedAbeona Therapeutics, Inc112020-01-102022-12-05
Pregabalin Treatment for RDEB Pain and Itch
Pregabalin - Pain, Neuropathic, Itch
Phase 3CompletedThe Hospital for Sick Children12019-08-072025-01-22
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
PTX-022, Placebo - Pachyonychia Congenita
Phase 2 / Phase 3CompletedPalvella Therapeutics, Inc.732019-04-012024-08-29
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream - Sjogren-Larsson Syndrome
Phase 3CompletedAldeyra Therapeutics, Inc.112018-07-182023-02-09
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex
Botulinic toxin, Placebo - Epidermolysis Bullosa Simplex
Phase 2 / Phase 3CompletedUniversity Hospital, Toulouse182018-06-142026-09-21
Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Oleogel-S10, Control gel - Epidermolysis Bullosa
Phase 3CompletedAmryt Research Limited2232017-03-292023-07-20
Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)
Irbesartan, Placebo - Ehlers-Danlos Syndrome, Vascular Type
Phase 3CompletedAssistance Publique - Hôpitaux de Paris612016-01-012024-02-29
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
SD-101-6.0 cream, Placebo (SD-101-0.0) cream - Epidermolysis Bullosa
Phase 3CompletedScioderm, Inc.1692015-03-112020-04-09
Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side - Lamellar Ichthyosis
Phase 3CompletedCentre Hospitalier Universitaire de Nice62010-10-012026-06-17
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
Rezular 15mg, Placebo, Rezular - Irritable Bowel Syndrome With Diarrhea
Phase 3CompletedAGI Therapeutics, Inc.7112007-09-012009-06-11
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
Campath 1H, Cyclophosphamide, Fludarabine - Dyskeratosis Congenita, Aplastic Anemia
Phase 2 / Phase 3CompletedMasonic Cancer Center, University of Minnesota362007-08-012017-12-05
Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis
Liarozole - Ichthyosis, Lamellar
Phase 2 / Phase 3CompletedStiefel, a GSK Company982006-01-012011-09-26
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
monolaurin cream - Ichthyosis
Phase 3CompletedCellegy Pharmaceuticals901996-09-012015-03-25

Narrower conditions

Epidermolysis Bullosa (4)  ·  Epidermolysis Bullosa Dystrophica (3)  ·  Pachyonychia Congenita (3)  ·  Ichthyosis (2)  ·  Ichthyosis, Lamellar (2)  ·  Anemia, Aplastic (1)  ·  Blister (1)  ·  Dyskeratosis Congenita (1)  ·  Ehlers-Danlos Syndrome, Type IV (1)  ·  Epidermolysis Bullosa Simplex (1)  ·  Ichthyosis Bullosa of Siemens (1)  ·  Neuralgia (1)  ·  Pruritus (1)  ·  Rare Diseases (1)  ·  Sjogren-Larsson Syndrome (1)

Broader conditions

Congenital Abnormalities (18)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18)  ·  Skin and Connective Tissue Diseases (18)  ·  Skin Diseases (17)  ·  Genetic Diseases, Inborn (16)  ·  Skin Diseases, Genetic (16)  ·  Skin Diseases, Vesiculobullous (7)  ·  Infant, Newborn, Diseases (6)  ·  Keratosis (6)  ·  Collagen Diseases (4)  ·  Connective Tissue Diseases (4)  ·  Ichthyosis (4)  ·  Abnormalities, Multiple (3)  ·  Ectodermal Dysplasia (3)

Interventions

Alemtuzumab (1)  ·  Antilymphocyte Serum (1)  ·  Bone Marrow Transplantation (1)  ·  Cyclophosphamide (1)  ·  Drugs, Investigational (1)  ·  Irbesartan (1)  ·  Methylprednisolone (1)  ·  Pregabalin (1)  ·  Radiotherapy (1)  ·  Skin Cream (1)  ·  Stem Cell Transplantation (1)  ·  Whole-Body Irradiation (1)  ·  abobotulinumtoxinA (1)  ·  episalvan (1)  ·  fludarabine (1)

Sponsors

Palvella Therapeutics, Inc. (3)  ·  Krystal Biotech, Inc. (2)  ·  AGI Therapeutics, Inc. (1)  ·  Abeona Therapeutics, Inc (1)  ·  Aldeyra Therapeutics, Inc. (1)  ·  Amryt Research Limited (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Cellegy Pharmaceuticals (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  LEO Pharma (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Scioderm, Inc. (1)  ·  Stiefel, a GSK Company (1)  ·  The Hospital for Sick Children (1)  ·  University Hospital, Toulouse (1)

Countries

United States (12)  ·  France (7)  ·  Germany (4)  ·  Italy (4)  ·  Canada (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Austria (2)  ·  Israel (2)  ·  Netherlands (2)  ·  Serbia (2)  ·  Spain (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)

Top investigators

David Hansen, MD (2)  ·  Joyce Teng, MD (2)  ·  Amy Paller, MD (1)  ·  Carl R. Thornfeldt (1)  ·  Chiaverini Christine, Dr (1)  ·  David Chien, MD (1)  ·  Jakub Tolar, M.D., Ph.D. (1)  ·  Jean Tang, MD (1)  ·  Johannes S Kern, MD PhD (1)  ·  Juliette Mazereeuw-Hautier, MD (1)  ·  Koen van Rossem, MD, PhD (1)

Results publications

PMID 20383216, PMID 20825986, PMID 23630948, PMID 24102348, PMID 31186047, PMID 32576219, PMID 32693833, PMID 36516090, PMID 39441591, PMID 39906986, PMID 40220208, PMID 40570869, PMID 42205007

NIH funding

2014 (1), 2015 (1), 2016 (1), 2017 (1)